36.89
+0.84(+2.33%)
Currency In USD
| Previous Close | 36.05 |
| Open | 36.45 |
| Day High | 39.15 |
| Day Low | 35.87 |
| 52-Week High | 47.65 |
| 52-Week Low | 8.24 |
| Volume | 1.99M |
| Average Volume | 1.48M |
| Market Cap | 2.45B |
| PE | -12.63 |
| EPS | -2.92 |
| Moving Average 50 Days | 40.98 |
| Moving Average 200 Days | 23.43 |
| Change | 0.84 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $2,000.54 as of December 14, 2025 at a share price of $36.89. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $3,033.72 as of December 14, 2025 at a share price of $36.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
GlobeNewswire Inc.
Dec 12, 2025 4:00 PM GMT
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 1
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc.
Nov 07, 2025 11:10 PM GMT
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS),